scholarly journals Plasma heat shock protein response to euglycemia in type 2 diabetes

2021 ◽  
Vol 9 (1) ◽  
pp. e002057
Author(s):  
Alexander S Atkin ◽  
Abu Saleh Md Moin ◽  
Ahmed Al-Qaissi ◽  
Thozhukat Sathyapalan ◽  
Stephen L Atkin ◽  
...  

IntroductionGlucose variability is associated with mortality and macrovascular diabetes complications. The mechanisms through which glucose variability mediates tissue damage are not well understood, although cellular oxidative stress is likely involved. As heat shock proteins (HSPs) play a role in the pathogenesis of type 2 diabetes (T2D) complications and are rapidly responsive, we hypothesized that HSP-related proteins (HSPRPs) would differ in diabetes and may respond to glucose normalization.Research design and methodsA prospective, parallel study in T2D (n=23) and controls (n=23) was undertaken. T2D subjects underwent insulin-induced blood glucose normalization from baseline 7.6±0.4 mmol/L (136.8±7.2 mg/dL) to 4.5±0.07 mmol/L (81±1.2 mg/dL) for 1 hour. Control subjects were maintained at 4.9±0.1 mmol/L (88.2±1.8 mg/dL). Slow Off-rate Modified Aptamer-scan plasma protein measurement determined a panel of HSPRPs.ResultsAt baseline, E3-ubiquitin-protein ligase (carboxyl-terminus of Hsc70 interacting protein (CHIP) or HSPABP2) was lower (p=0.03) and ubiquitin-conjugating enzyme E2G2 higher (p=0.003) in T2D versus controls. Following glucose normalization, DnaJ homolog subfamily B member 1 (DNAJB1 or HSP40) was reduced (p=0.02) in T2D, with HSP beta-1 (HSPB1) and HSP-70-1A (HSP70-1A) (p=0.07 and p=0.09, respectively) also approaching significance relative to T2D baseline levels.ConclusionsKey HSPRPs involved in critical protein interactions, CHIP and UBE2G2, were altered in diabetes at baseline. DNAJB1 fell in response to euglycemia, suggesting that HSPs are reacting to basal stress that could be mitigated by tight glucose control with reduction of glucose variability.

2018 ◽  
Vol 21 (5) ◽  
pp. 364-375 ◽  
Author(s):  
Ivan I. Dedov ◽  
Vsevolod A. Tkachuk ◽  
Nikolai B. Gusev ◽  
Vladimir P. Shirinsky ◽  
Aleksandr V. Vorotnikov ◽  
...  

Type 2 diabetes mellitus (T2DM) is a socially important disease with only symptomatic therapy developed due to lack of knowledge about its pathogenesis and underlying mechanism. Insulin resistance (IR) is the first link of T2DM pathogenesis and results in decrease of ability of insulin to stimulate glucose uptake by target cells. Development of IR involves genetic predisposition, excessive nutrition, stress, obesity or chronic inflammation due to disruption of insulin signaling within cells. Molecular mechanisms and markers of IR are characterized rather poorly, which prevents early diagnosis and creation of preventive therapy. Euglycemic clamp test is still a golden standard for IR diagnosis in clinic. Hyperglycemia is a distant consequence of IR in which damaging effect of oxidative and carbonyl stress is realized and diagnosis of T2DM is stipulated. Molecular chaperones and small heat-shock proteins have a protective effect at the early stages of T2DM pathogenesis, preventing development of reticulum stress and apoptosis. Endothelial dysfunction is related to T2DM and its cardiovascular complications, however, it is unknown on which stage of pathogenesis these changes occur and what are their molecular inductors. Finally, transcriptional activity and adipogenic differentiation play an important role in formation of new fat depots from predecessor cells and activation of brown and beige fat demonstrating hypolipidemic and hypoglycemic properties. The aim of this study was investigation of pathophysiological mechanisms of development of IR and endothelial dysfunction, role of transcription factor Prep1 and small heat shock proteins, evaluation of novel methods of diagnostics of IR and therapeutic potential of brown and beige fat, determination of biotargets for new antidiabetic drugs.


2021 ◽  
Author(s):  
Niala den Braber ◽  
Miriam M.R. Vollenbroek-Hutten ◽  
Kathryn M. Westerik ◽  
Stephan J.L. Bakker ◽  
Gerjan Navis ◽  
...  

OBJECTIVE To investigate glucose variations associated with HbA<sub>1c</sub> in insulin treated patients with type 2 diabetes. <p>RESEARCH DESIGN AND METHODS Patients included in the Diabetes and Lifestyle Cohort Twente (DIALECT)-2 (n=79) were categorized in three HbA<sub>1c</sub> categories: low, intermediate and high (≤ 53; 54–62 and ≥ 63 mmol/mol or ≤ 7, 7.1–7.8, ≥ 7.9%). Blood glucose time in range (TIR), time below range (TBR), time above range (TAR), glucose variability parameters, day and night duration and frequency of TBR and TAR episodes were determined by continuous glucose monitoring (CGM), using the FreeStyle Libre sensor and compared between HbA<sub>1c</sub> categories.</p> <p>RESULTS <a>CGM was performed for a median [interquartile range] of 10 [7-12] days/ patient. </a>TIR was not different for low and intermediate HbA<sub>1c</sub> categories:<sub> </sub>(76.8% [68.3–88.2] vs 76.0% [72.5.0–80.1]), whereas in the low category<sub> </sub>TBR was higher and TAR lower (7.7% [2.4–19.1] vs 0.7% [0.3–6.1], and 8.2% [5.7–17.6] vs 20.4% [11.6–27.0], respectively, <i>p </i>< 0.05). Patients in the highest HbA<sub>1c </sub>category had lower TIR (52.7% [40.9–67.3]) and higher TAR (44.1% [27.8–57.0]) than the other HbA<sub>1c </sub>categories (<i>p</i> < 0.05), but did not have less TBR during the night. All patients had more (0.06 ± 0.06/h vs 0.03 ± 0.03/h, <i>p </i>= 0.002) and longer (88.0 [45.0–195.5] vs 53.4 [34.4–82.8] minutes, <i>p </i>< 0.001) TBR episodes during the night than during the day. </p> <p>CONCLUSIONS In this study, a high HbA<sub>1c</sub> did not reduce the occurrence of nocturnal hypoglycemia and low HbA<sub>1c</sub> was not associated with the highest TIR. Optimal personalization of glycemic control requires the use of newer tools, including CGM-derived parameters. <br> </p>


2020 ◽  
Vol 21 (21) ◽  
pp. 8204 ◽  
Author(s):  
Joanne Elizabeth Rowles ◽  
Kevin Noel Keane ◽  
Thiago Gomes Heck ◽  
Vinicius Cruzat ◽  
Giuseppe Verdile ◽  
...  

Type 2 diabetes (T2D) and Alzheimer’s disease (AD) are growing in prevalence worldwide. The development of T2D increases the risk of AD disease, while AD patients can show glucose imbalance due to an increased insulin resistance. T2D and AD share similar pathological features and underlying mechanisms, including the deposition of amyloidogenic peptides in pancreatic islets (i.e., islet amyloid polypeptide; IAPP) and brain (β-Amyloid; Aβ). Both IAPP and Aβ can undergo misfolding and aggregation and accumulate in the extracellular space of their respective tissues of origin. As a main response to protein misfolding, there is evidence of the role of heat shock proteins (HSPs) in moderating T2D and AD. HSPs play a pivotal role in cell homeostasis by providing cytoprotection during acute and chronic metabolic stresses. In T2D and AD, intracellular HSP (iHSP) levels are reduced, potentially due to the ability of the cell to export HSPs to the extracellular space (eHSP). The increase in eHSPs can contribute to oxidative damage and is associated with various pro-inflammatory pathways in T2D and AD. Here, we review the role of HSP in moderating T2D and AD, as well as propose that these chaperone proteins are an important link in the relationship between T2D and AD.


2015 ◽  
Vol 29 (4) ◽  
pp. 578-588 ◽  
Author(s):  
Kanhaiya Singh ◽  
Neeraj K. Agrawal ◽  
Sanjeev K. Gupta ◽  
Gyanendra Mohan ◽  
Sunanda Chaturvedi ◽  
...  

2019 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Arash Ghorbani Abdi Saedabad ◽  
Reyhane Rezaie ◽  
Seyed Usef Javadmoossavi ◽  
Gholamraza Anani Sarab ◽  
Mohammad Malekaneh ◽  
...  

2008 ◽  
Vol 14 (2) ◽  
pp. 113-115 ◽  
Author(s):  
Philip L. Hooper ◽  
Paul L. Hooper

2021 ◽  
Author(s):  
Niala den Braber ◽  
Miriam M.R. Vollenbroek-Hutten ◽  
Kathryn M. Westerik ◽  
Stephan J.L. Bakker ◽  
Gerjan Navis ◽  
...  

OBJECTIVE To investigate glucose variations associated with HbA<sub>1c</sub> in insulin treated patients with type 2 diabetes. <p>RESEARCH DESIGN AND METHODS Patients included in the Diabetes and Lifestyle Cohort Twente (DIALECT)-2 (n=79) were categorized in three HbA<sub>1c</sub> categories: low, intermediate and high (≤ 53; 54–62 and ≥ 63 mmol/mol or ≤ 7, 7.1–7.8, ≥ 7.9%). Blood glucose time in range (TIR), time below range (TBR), time above range (TAR), glucose variability parameters, day and night duration and frequency of TBR and TAR episodes were determined by continuous glucose monitoring (CGM), using the FreeStyle Libre sensor and compared between HbA<sub>1c</sub> categories.</p> <p>RESULTS <a>CGM was performed for a median [interquartile range] of 10 [7-12] days/ patient. </a>TIR was not different for low and intermediate HbA<sub>1c</sub> categories:<sub> </sub>(76.8% [68.3–88.2] vs 76.0% [72.5.0–80.1]), whereas in the low category<sub> </sub>TBR was higher and TAR lower (7.7% [2.4–19.1] vs 0.7% [0.3–6.1], and 8.2% [5.7–17.6] vs 20.4% [11.6–27.0], respectively, <i>p </i>< 0.05). Patients in the highest HbA<sub>1c </sub>category had lower TIR (52.7% [40.9–67.3]) and higher TAR (44.1% [27.8–57.0]) than the other HbA<sub>1c </sub>categories (<i>p</i> < 0.05), but did not have less TBR during the night. All patients had more (0.06 ± 0.06/h vs 0.03 ± 0.03/h, <i>p </i>= 0.002) and longer (88.0 [45.0–195.5] vs 53.4 [34.4–82.8] minutes, <i>p </i>< 0.001) TBR episodes during the night than during the day. </p> <p>CONCLUSIONS In this study, a high HbA<sub>1c</sub> did not reduce the occurrence of nocturnal hypoglycemia and low HbA<sub>1c</sub> was not associated with the highest TIR. Optimal personalization of glycemic control requires the use of newer tools, including CGM-derived parameters. <br> </p>


Sign in / Sign up

Export Citation Format

Share Document